The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab–mepolizumab treatment efficiency in these patients

Şeyma Özden,Fatma Merve Tepetam,Cihan Örçen,Tuğçe Yakut

DOI: https://doi.org/10.1097/md.0000000000035247

IF: 1.6

2024-02-10

Medicine

Abstract:The worldwide prevalence of overweight and obesity has nearly tripled over the past 4 decades, and represents one of the most serious unmet public health challenges of the 21st century. [ 1 ] Obesity is a risk factor for many life-threatening conditions such as atherosclerosis, hypertension and type 2 diabetes mellitus. Obesity has also been proven to be a major risk factor for asthma. [ 2 ] Asthma with obese patients is usually severe and difficult to control. [ 3 ] Although severe asthma accounts for only 10% of all asthma cases, the severe asthma patient group accounts for 60% of the total medical cost of asthma treatment. [ 3 , 4 ] Considering that up to 60% of patients with severe asthma are obese, it is obvious that this is a major health problem and socio-economic burden. [ 5 ] The obese asthma phenotype varies both clinically and physiologically depending upon whether asthma develops before or after the onset of obesity. Asthma with subsequent obesity is characterized by early-onset disease (typically < 12 years of age), elevated markers of allergic inflammation (atopy, allergic symptoms, elevated serum immunoglobulin E level), more severe physiological changes (airway obstruction and hypersensitivity) whereas asthma developing after obesity is characterized by a later onset disease (≥12 years of age), female dominance, less allergic inflammation, less airflow obstruction, and less hypersensitivity. [ 6 ]

medicine, general & internal